Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Histologic conversion in the non-Hodgkin's lymphomas.

B Acker, R T Hoppe, T V Colby

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |January 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Getting the right blood to the right patient: the contribution of near-miss event reporting and barrier analysis.

    Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2005
    Same author

    Event reporting systems: MERS-TM, surveillance--seeing and using the data below the waterline.

    Developments in biologicals·2005
    Same author

    Organization of event reporting data for sense making and system improvement.

    Quality & safety in health care·2003
    Same author

    Reporting of near-miss events for transfusion medicine: improving transfusion safety.

    Transfusion·2001
    Same author

    Protein C and S deficiency.

    Seminars in thrombosis and hemostasis·1999
    Same author

    Identification and classification of the causes of events in transfusion medicine.

    Transfusion·1998
    Same journal

    Biology Over Monotherapy: Mature Results From European Organisation For Research and Treatment of Cancer 22033-26033 Reaffirm Molecular Stratification, Not Treatment Sequence, Defines Prognosis in Low-Grade Glioma.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk Model.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Efficacy and Tolerability of Zenocutuzumab in Advanced <i>NRG1</i> Fusion-Positive Cholangiocarcinoma: Results From the eNRGy Phase II Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Phase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    Same journal

    Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.2.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
    See all related articles

    Histologic conversion in non-Hodgkin's lymphoma occurred in 28% of patients, with a higher actuarial risk. Conversion often led to aggressive disease, but achieving complete remission post-conversion improved survival.

    Area of Science:

    • Oncology
    • Hematology
    • Clinical Trials

    Background:

    • Non-Hodgkin's lymphoma (NHL) comprises various subtypes with differing prognoses.
    • Favorable subtypes of NHL were historically treated with radiation or chemotherapy.
    • Understanding treatment outcomes and disease progression is crucial for patient management.

    Purpose of the Study:

    • To analyze treatment outcomes in patients with favorable NHL subtypes.
    • To investigate the incidence and impact of histologic conversion to unfavorable subtypes.
    • To identify factors associated with histologic conversion and its effect on survival.

    Main Methods:

    • Prospective randomized clinical trials involving 150 patients with favorable NHL subtypes.
    • Treatments included various combinations of chemotherapy (CVP, C-MOPP) and irradiation (involved field, total lymphoid, whole body).

    Related Experiment Videos

  • Assessment of complete response rates, relapse, and histologic conversion over time.

    • Main Results:

    • Initial complete response rate was 79%.
    • Histologic conversion to unfavorable NHL subtypes occurred in 28% of patients who relapsed or did not achieve initial remission, with an 8-year actuarial risk of 60%.
    • Conversion was often linked to aggressive disease, with median survival under 1 year, but achieving remission post-conversion improved 5-year survival to 75%.

    Conclusions:

    • Histologic conversion is a significant event in NHL, often associated with poor prognosis.
    • While conversion poses risks, achieving complete remission after conversion can lead to favorable outcomes.
    • No specific predictive risk factors for histologic conversion were identified in this cohort.